LB-208, LB-208
LB208-1-002
Phase 2 small_molecule active
Quick answer
LB-208, LB-208 for Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS) is a Phase 2 program (small_molecule) at AOP Orphan Pharmaceuticals GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AOP Orphan Pharmaceuticals GmbH
- Indication
- Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active